Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Senthil Damodaran

12PUBLICATIONS

140CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunology

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|Jan 12, 2026

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.

Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos H Barcenas

|Jul 11, 2025

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors.

Blessie Elizabeth Nelson, Filip Janku, Siqing Fu

|Jan 22, 2025

Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.

Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava

|Nov 25, 2024

Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.

Funda Meric-Bernstam, Erkan Yuca, Kurt W Evans

|Oct 02, 2024

Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study.

Clinton Yam, Miral Patel, Holly A Hill

|Apr 23, 2024

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.

Aditya Bardia, Ian E Krop, Takahiro Kogawa

Pageof 2

Frequent Collaborators

6 joint publications

Debu Tripathy

4 joint publications

Funda Meric-Bernstam

3 joint publications

Banu K Arun

2 joint publications

Jennifer K Litton

2 joint publications

Lei Huo

2 joint publications

Elizabeth A Mittendorf

2 joint publications

Roland L Bassett

2 joint publications

Jason B White

2 joint publications

Aysegul A Sahin

2 joint publications

Akshara Singareeka Raghavendra

Frequent Collaborators

6 joint publications

Debu Tripathy

4 joint publications

Funda Meric-Bernstam

3 joint publications

Banu K Arun

2 joint publications

Jennifer K Litton

Top Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on : Jun 13, 2014

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on : Sep 25, 2018

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on : May 09, 2025

See more related videos

Top Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on : Jun 13, 2014

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on : Sep 25, 2018

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on : May 09, 2025

See more related videos